Compare AbbVie Inc (ABBV) vs Essex Property Trust, Inc. (ESS) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Essex Property Trust (ESS) trades at $298.32, showing minimal daily change. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported robust earnings, beating estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.47. Revenue reached $1.89B in 2025, supported by high gross and net income margins. Recent developments include a $2.59 dividend declaration and inclusion in the Russell Microcap Index.

Outlook remains positive due to strong West Coast rental demand and AI-driven employment growth, but risks include high debt levels and Seattle market weakness. Analyst consensus is mixed with a $291.68 price target, suggesting limited upside from current levels. Investment appeal hinges on sustained rental growth and balance sheet management amid economic uncertainty.